EX-99.1 2 q22020financialresults.htm EX-99.1 Document

Exhibit 99.1
tricidalogoa031.jpg
FOR IMMEDIATE RELEASE

Tricida Announces Second Quarter 2020 Financial Results
Webcast Today at 4:30 pm Eastern Time
SOUTH SAN FRANCISCO, Calif., August 5, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and six months ended June 30, 2020 and provided an update on key initiatives.
Recent Events
•On May 22, 2020, Tricida completed an offering of $200.0 million of its 3.50% Convertible Senior Notes due 2027. Net proceeds from the offering were $193.3 million, after deducting underwriting discounts and commissions and other offering costs.
•In early July, Tricida deployed its field force of approximately 40 Specialty Account Managers in key geographic regions to communicate directly with 70% to 80% of the 5,000 highest-prescribing nephrologists in the United States. The Specialty Account Managers have initiated metabolic acidosis disease awareness education, and to date, have conducted nearly 6000 virtual or in-person engagements with nephrologists and their staff, hosted numerous nephrologists’ roundtable meetings and arranged peer-to-peer educational events.
•On July 14, 2020, Tricida received a notification from the U.S. Food and Drug Administration (FDA) stating that, as part of its ongoing review of the company’s New Drug Application (NDA), the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. The notification does not specify the deficiencies identified by the FDA. The FDA stated that the notification does not reflect a final decision on the information under review. The company plans to work with the FDA to identify and seek to resolve the deficiencies.



Upcoming Events and Projected Milestones
•The FDA assigned a Prescription Drug User Fee Act, or PDUFA, goal date of August 22, 2020 for the potential approval to market veverimer in the United States. Tricida anticipates that it will receive further clarification related to the FDA notification of July 14, 2020 on or before the PDUFA goal date of August 22, 2020. While the company has no additional information from the FDA since the July 14, 2020 notification, at this time, the company believes it is unlikely to receive approval to market veverimer in the United States on the PDUFA goal date.
•Tricida plans to complete enrollment of patients in its VALOR-CKD confirmatory postmarketing trial in first half of 2021. The VALOR-CKD trial is an outcomes trial comparing veverimer versus placebo in time to renal disease progression in patients with metabolic acidosis and chronic kidney disease (CKD).
“While we won’t speculate what the FDA notification may entail, we are preparing for all eventualities to swiftly resolve any potential issues. However, we remain confident in the fundamentals of veverimer and its underlying value proposition,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “I am reassured by the feedback that we have received from our Specialty Account Managers from their initial interactions with community nephrologists that confirms the unmet need to treat metabolic acidosis.”
Financial Results for the Three and Six Months Ended June 30, 2020
Research and development expense was $28.8 million and $29.0 million for the three months ended June 30, 2020 and 2019, respectively, and $78.1 million and $60.4 million for the six months ended June 30, 2020 and 2019, respectively. The decrease in research and development expense for the three months ended June 30, 2020 compared to the prior year was primarily due to decreased activities in connection with our veverimer clinical development program related to reduced expenditures in our clinical trials, partially offset by an increase in manufacturing process optimization and increased personnel costs. The increase in research and development expense for the six months ended June 30, 2020 compared to the prior year was primarily due to increased activities in connection with our veverimer clinical development program related to manufacturing process optimization and the manufacturing of drug substance, as well as increased personnel costs.
General and administrative expense was $28.4 million and $8.9 million for the three months ended June 30, 2020 and 2019, respectively, and $51.9 million and $15.2 million for the six months ended June 30, 2020 and 2019, respectively. The increases in general and administrative expense in the three and six months ended June 30, 2020 compared to the three and six months ended June 30, 2019 were primarily due to increased administrative costs supporting the increased activities in connection with our veverimer clinical development program, including pre-commercialization, Medical Affairs, professional service costs, and increased personnel costs.
Net loss was $58.2 million (non-GAAP net loss of $48.9 million) and $36.6 million (non-GAAP net loss of $31.5 million) for the three months ended June 30, 2020 and 2019, respectively, and $132.3 million (non-GAAP net loss of $112.8 million) and $74.5 million (non-GAAP net loss of $65.9 million) for the six months ended June 30, 2020 and 2019, respectively. Net loss per basic and diluted share was $1.16 and


$0.75 for the three months ended June 30, 2020 and 2019, respectively, and $2.65 and $1.64 for the six months ended June 30, 2020 and 2019, respectively.
As of June 30, 2020, cash, cash equivalents and investments were $436.9 million.
Today’s Conference Call and Webcast
Tricida will host a conference call today at 4:30 pm Eastern Time to discuss its financial results and business progress. Please access the Tricida Conference Call as follows:

Tricida Second Quarter 2020 Conference Call

4:30 pm Eastern Time Today
Webcast:IR.Tricida.com
Dial-in:(877) 377-5478
International:(629) 228-0740
Conference ID:8994536
A replay of the webcast will be available on the Investor Relations page of Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida is currently conducting its confirmatory postmarketing trial, VALOR-CKD, of veverimer. The Tricida NDA for veverimer has been accepted for review by the FDA through the Accelerated Approval Program. The FDA has assigned a PDUFA goal date of August 22, 2020.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to all of the statements under the heading “Upcoming Events and Projected Milestones” and other statements, including the potential receipt and timing of the FDA’s approval of the NDA, the potential receipt and timing of further clarification related to the FDA notification of July 14, 2020, the potential availability of the Accelerated Approval Program, as well as the approvability of veverimer under that program, the Company’s expectations with regard to its interactions


and communications with the FDA, plans and expectations as to the PDUFA date, and statements regarding the therapeutic potential of, and potential clinical and commercial development plans for, veverimer. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, that we may not be able to address all of the issues that relate to the deficiencies the FDA may identify with respect to veverimer; that we may not be able to achieve upcoming milestones; the cost, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis, or at all; there can be no assurance that the FDA would approve an NDA through the Accelerated Approval Program, or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; possible safety and efficacy concerns; and that we completely rely on third-party suppliers and manufacturers for many aspects of our business. These and other factors that may affect our future results of operations are identified and described in more detail in our filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report filed on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.
You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

(Financial Tables to Follow)


Tricida, Inc.

Condensed Balance Sheets
(Unaudited)
(In thousands)
June 30,
2020		December 31, 2019
Assets
Current assets:
Cash and cash equivalents$41,900  $18,574  
Short-term investments345,632  289,424  
Prepaid expenses and other current assets9,830  4,744  
Total current assets397,362  312,742  
Long-term investments49,371  46,980  
Property and equipment, net1,432  2,728  
Operating lease right-of-use assets8,734  9,376  
Total assets$456,899  $371,826  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$5,839  $5,911  
Current operating lease liabilities1,088  1,072  
Current Term Loan6,784  —  
Accrued expenses and other current liabilities20,769  32,780  
Total current liabilities34,480  39,763  
Non-current Term Loan, net67,952  58,374  
Convertible Senior Notes, net114,645  —  
Non-current operating lease liabilities8,515  8,783  
Other long-term liabilities327  1,023  
Total liabilities225,919  107,943  
Stockholders’ equity:
Preferred stock—  —  
Common stock50  50  
Additional paid-in capital731,358  632,647  
Accumulated other comprehensive income (loss)863  193  
Accumulated deficit(501,291) (369,007) 
Total stockholders’ equity230,980  263,883  
Total liabilities and stockholders’ equity$456,899  $371,826  



Tricida, Inc.

Condensed Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share amounts)
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2020201920202019
Operating expenses:
Research and development$28,757  $28,976  $78,138  $60,399  
General and administrative28,418  8,861  51,944  15,213  
Total operating expenses57,175  37,837  130,082  75,612  
Loss from operations(57,175) (37,837) (130,082) (75,612) 
Other income (expense), net2,675  2,602  3,488  3,869  
Interest expense(3,756) (1,391) (5,776) (2,780) 
Loss before income taxes(58,256) (36,626) (132,370) (74,523) 
Income tax benefit86  —  86  —  
Net loss(58,170) (36,626) (132,284) (74,523) 
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale investments, net of tax902  480  670  782  
Total comprehensive loss$(57,268) $(36,146) $(131,614) $(73,741) 
Net loss per share, basic and diluted$(1.16) $(0.75) $(2.65) $(1.64) 
Weighted-average number of shares outstanding, basic and diluted49,960,072  48,674,238  49,900,739  45,489,861  





Tricida, Inc.

GAAP to non-GAAP reconciliations
(Unaudited)
(In thousands)
A reconciliation between net loss on a GAAP basis and on a non-GAAP basis is as follows:
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2020201920202019
GAAP net loss, as reported$(58,170) $(36,626) $(132,284) $(74,523) 
Adjustments:
Non-cash operating lease costs70  209  390  413  
Stock-based compensation9,079  4,413  17,453  7,071  
Accretion of Term Loan and Convertible Senior Notes1,580  523  2,331  1,011  
Changes in fair value of compound derivative liability
(1,496) (9) (650) 165  
Total adjustments9,233  5,136  19,524  8,660  
Non-GAAP net loss$(48,937) $(31,490) $(112,760) $(65,863) 
Use of Non-GAAP Financial Measures
We supplement our financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss and diluted earnings per share, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss” is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss adjusted to exclude (1) non-cash operating lease costs, (2) stock-based compensation, (3) accretion of Term Loan and Convertible Senior Notes and (4) changes in fair value of compound derivative liability, in reconciling of our GAAP to Non-GAAP net loss. Non-GAAP financial measures used by Tricida may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

#####

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com